Blood Test Protein Panel for Alzheimer's Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing Alzheimer's disease in primary care settings are inefficient and costly, leading to delayed treatment and increased healthcare costs due to the need for extensive diagnostic procedures, which are often not adequately addressed in limited time frames.
Innovation Solution
A blood test that measures the expression levels of specific proteins (FABP, beta 2 microglobulin, PPY, sTNFR1, CRP, VCAM-1, thrombopoietin, TNF-α, tenascin C, IL-5, IL-6, IL-7, IL-10, IL-18, Factor VII, TARC, SAA, and ICAM-1) to exclude patients from further diagnostic testing by comparing these levels to a statistically locked-down sample, thereby reducing the need for invasive procedures.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If extensive diagnostic procedures are used to diagnose Alzheimer's disease, then diagnostic accuracy is improved, but healthcare costs and time consumption increase
Solution Approach 1:
The diagnostic process is segmented into two stages: (1) a preliminary blood-based protein panel screening test that measures multiple proteins simultaneously to identify patients at risk, and (2) a secondary confirmatory diagnostic stage for only those who screen positive. This segmentation allows most patients to be quickly cleared through the efficient blood test while maintaining accurate diagnosis through the comprehensive second-stage evaluation only when needed.
Solution Approach 2:
The invention performs a preliminary screening action using a blood test that measures multiple protein markers (including tau, beta-amyloid, and other neurodegeneration-related proteins) before committing patients to extensive diagnostic procedures. This preliminary action filters out patients who do not have Alzheimer's disease, allowing the full diagnostic workup to be reserved only for those who truly need it, thereby reducing overall time consumption while maintaining diagnostic accuracy.
2Measurement precision
If extensive diagnostic procedures are used to diagnose Alzheimer's disease, then diagnostic accuracy is improved, but healthcare costs increase
Solution Approach 1:
The diagnostic pathway is divided into a cost-effective preliminary blood-based protein panel screening followed by a more expensive confirmatory diagnostic stage only for screen-positive patients. This segmentation dramatically reduces overall healthcare costs by avoiding unnecessary expensive procedures for patients who would not have Alzheimer's disease, while still maintaining high diagnostic accuracy through the two-stage approach.
Solution Approach 2:
The blood-based protein panel serves as an intermediary screening tool between the initial clinical suspicion and the expensive definitive diagnostic procedures. This intermediary test provides a cost-effective filter that maintains diagnostic accuracy by identifying which patients truly need the comprehensive (and expensive) workup, thereby reducing overall healthcare expenditure while preserving measurement precision.
3Productivity
If a simple blood test is used for screening, then time consumption and costs are reduced, but diagnostic accuracy may decrease
Solution Approach 1:
The screening test uses a composite approach by simultaneously measuring multiple protein markers (tau, beta-amyloid, and other neurodegeneration-related proteins) in a single blood sample rather than relying on a single marker. This composite multi-protein panel maintains high diagnostic accuracy comparable to more complex diagnostic procedures while preserving the advantages of a simple, rapid, and cost-effective blood-based screening method.
Data Source
AI summary
The present invention includes a method for excluding patients from the need for further analysis of Alzheimer's Disease comprising: obtaining a blood or serum sample from a patient in a primary care setting; determining the expression levels of at least 4 of the following proteins: FABP, beta 2 microglobulin, PPY, soluble tumor necrosis factor receptor 1 (sTNFR1), CRP, VCAM-1, thrombopoietin, α2 macroglobulin, eotaxin 3, tumor necrosis factor-alpha (TNF-α), tenascin C (TNC), IL-5, IL-6, IL-7, IL-10, IL-18, 1309, Factor VII, thymus and activation-regulated chemokine (TARC), serum amyloid A (SAA), and intercellular cell-adhesion molecule-1 (ICAM-1); comparing the level of expression from the sample with a statistically locked-down, multi-ethnic, broad age spectrum statistical sample; and determining if the patient is excluded from further testing for Alzheimer's Disease, thereby eliminating the need for further testing of the patient.